APA
Ruíz-Borrego M., Guerrero-Zotano A., Bermejo B., Ramos M., Cruz J., Baena-Cañada J. M., Cirauqui B., Rodríguez-Lescure Á., Alba E., Martínez-Jáñez N., Muñoz M., Antolín S., Álvarez I., Del Barco S., Sevillano E., Chacón J. I., Antón A., Escudero M. J., Ruiz V., Carrasco E. & Martín M. (20191220). Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. : Breast cancer research and treatment.
Chicago
Ruíz-Borrego Manuel, Guerrero-Zotano Angel, Bermejo Begoña, Ramos Manuel, Cruz Josefina, Baena-Cañada Jose Manuel, Cirauqui Beatriz, Rodríguez-Lescure Álvaro, Alba Emilio, Martínez-Jáñez Noelia, Muñoz Montserrat, Antolín Silvia, Álvarez Isabel, Del Barco Sonia, Sevillano Elena, Chacón José Ignacio, Antón Antonio, Escudero María José, Ruiz Victoria, Carrasco Eva and Martín Miguel. 20191220. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. : Breast cancer research and treatment.
Harvard
Ruíz-Borrego M., Guerrero-Zotano A., Bermejo B., Ramos M., Cruz J., Baena-Cañada J. M., Cirauqui B., Rodríguez-Lescure Á., Alba E., Martínez-Jáñez N., Muñoz M., Antolín S., Álvarez I., Del Barco S., Sevillano E., Chacón J. I., Antón A., Escudero M. J., Ruiz V., Carrasco E. and Martín M. (20191220). Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. : Breast cancer research and treatment.
MLA
Ruíz-Borrego Manuel, Guerrero-Zotano Angel, Bermejo Begoña, Ramos Manuel, Cruz Josefina, Baena-Cañada Jose Manuel, Cirauqui Beatriz, Rodríguez-Lescure Álvaro, Alba Emilio, Martínez-Jáñez Noelia, Muñoz Montserrat, Antolín Silvia, Álvarez Isabel, Del Barco Sonia, Sevillano Elena, Chacón José Ignacio, Antón Antonio, Escudero María José, Ruiz Victoria, Carrasco Eva and Martín Miguel. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. : Breast cancer research and treatment. 20191220.